SCHEMBL13037005

SCHEMBL13037005

CCC1CCCCN1S(=O)(=O)c1c(C)noc1C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 1/20 0.49
PSEN2 P49810 1/20 0.49
APH1B Q8WW43 1/20 0.49
NCSTN Q92542 1/20 0.49
APH1A Q96BI3 1/20 0.49
PSENEN Q9NZ42 1/20 0.49
POLB P06746 2/20 0.48
TSHR P16473 2/20 0.47
TP53 P04637 1/20 0.47
LMNA P02545 1/20 0.46
CHRM4 P08173 2/20 0.45
ALDH1A1 P00352 2/20 0.45
KMT2A Q03164 1/20 0.44
MCOLN3 Q8TDD5 1/20 0.44
MAPK1 P28482 1/20 0.43
PKM P14618 1/20 0.43
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAPT P10636 1/20 0.43
THRB P10828 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3591997 0.80 ALDH1A1 (0.47) POLBTSHRLMNAALDH1A1KMT2A
SCHEMBL13037000 0.75 KMT2A (0.52) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL13036995 0.74 PSEN1 (0.53) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL20507216 0.74 CHRM4 (0.66) POLBTSHRLMNACHRM4ALDH1A1
SCHEMBL13036996 0.70 KMT2A (0.55) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL13034821 0.69 LMNA (0.58) POLBTSHRLMNACHRM4ALDH1A1
SCHEMBL27331094 0.68 PSEN1 (0.54) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL16333479 0.68 TSHR (0.59) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL1753984 0.68 PSEN1 (0.54) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL13036997 0.68 KMT2A (0.52) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825112-B2 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof SANOFI-AVENTIS (FR) 2010-11-02 US disclosed
US-7825112-B2 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof SANOFI-AVENTIS (FR) 2010-11-02 US disclosed
US-20090018117-A1 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-01-15 US disclosed
US-20090018117-A1 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018117-A1 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF PKD2, QPCT, CCNT2 PSEN1 1898/4885PSEN2 1076/4885APH1B 1584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.